Clinical Trial Update: Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating thalidomide for malnutrition inflammation syndrome in peritoneal dialysis patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malnutrition

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Peritoneal Dialysis, Malnutrition | Phase 4 | Status: WITHDRAWN